Peripheral Blood Stem Cells
PreclinicalCell therapy
Peripheral Blood Stem Cells is one of 5 biologic programs targeting Chronic Granulomatous Disease Transplant. It is currently in Preclinical.
1
Indications
5
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Chronic Granulomatous Disease Transplant
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Preclinical
Busulfex
Akero TherapeuticsPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Peripheral Blood Stem Cells
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Granulomatous Disease Transplant1 trial
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02629120·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peripheral Blood Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details